Retigabine 2HCl

Catalog No.S4734 Batch:S473401

Technical Data

Formula	C₁₆H₁₈FN₃O₂.2HCl
Molecular Weight	376.25	CAS No.	150812-13-8
Solubility (25°C)*	In vitro	DMSO	75 mg/mL (199.33 mM)
		Water	75 mg/mL (199.33 mM)
		Ethanol	25 mg/mL (66.44 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Retigabine 2HCl (D-23129) is a novel anticonvulsant with activity in a broad range of seizure models. The mechanism of action involves opening of neuronal K(V)7.2-7.5 (formerly KCNQ2-5) voltage-activated K(+) channels.

Targets

KCNQ3/5 ^[2] (Cell-based assay)	KCNQ2/Q3 channels ^[2] (Cell-based assay)	KCQN4 ^[2] (Cell-based assay)
1.4 μM(EC50)	1.6 μM(EC50)	5.2 μM(EC50)

In vitro

Retigabine is a novel antiepileptic drug whose mechanism of action involves potassium channel opening activity in neuronal cells. Retigabine can markedly enhance KCNQ2/Q3 currents. In addition, retigabine also enhances slow channel deactivation. Retigabine has been shown to increase the synthesis of GABA in rat hippocampal slices and to enhance GABA-induced chloride currents in cultured rat cortical neurons. Retigabine has been shown to induce membrane hyperpolarization in neurones in rat hippocampal-entorhinal cortex slices and to exert potassium channel opening activity in neuronal cells. Retigabine enhances a linopirdine-sensitive current in differentiated PC12 cells^[1]. concentrations of RTG/EZG ≥10 μM are required to cause significant augmentation of the GABAA receptor response. The potency of RTG/EZG differs somewhat depending on the GABAA receptor subunit combination, with the following rank order: α1β3γ2=α1β2γ2 >α3β2γ2=α2β2γ2>α5β2γ2=α1β2(N265S)γ2=α1β1γ2. RTG/EZG exhibits only weak inhibitory effects at voltage-gated Nav and Cav channel currents at predominantly supratherapeutic concentrations. RTG/EZG does not interact significantly with glutamate receptors^[2].

In vivo

Retigabine enhances γ-aminobutyric acid (GABA)-ergic transmission in the central nervous system^[1]. Retigabine is rapidly absorbed and distributed with an oral bioavailability of 60% and a high volume of distribution of approximately 6.2 L/kg. Tolerability is good in humans when titrated up to its therapeutic dose range (600-1200 mg/day). Plasma protein binding of the drug is approximately 80%. The relatively high systemic bioavailability after oral administration suggests that retigabine is resistant to first-pass metabolism, a finding confirmed in multiple species. Retigabine is metabolized exclusively via phase II hepatic glucuronidation and acetylation. Gender differences in exposure have been noted, with female subjects exhibiting higher plasma concentrations of the drug after oral administration than male subjects. Excretion of retigabine appears to be predominantly renal. Depending on the behavioral endpoints analyzed, it appears that retigabine has a relatively poor therapeutic index (ratio between TD50 obtained in rotarod and ED50 obtained in maximal electroshock where maximal tonic extension of the hindlimbs was used as endpoint) in both mice (TD50/ED50 = 2.2) and rats (TD50/ED50 = 1.9) after i.p. administration. However, after p.o. administration in rats retigabine shows a therapeutic index of 28.8, which compares favorably with that reported for other antiepileptics, such as carbamazepine^[4].

Protocol (from reference)

Cell Assay:^{^[3]}	Cell lines HEK293 cells Concentrations 0.1, 0.3, 1 or 3 μM Incubation Time 4 h Method The retigabine incubation experiments are performed on HEK293 cells transfected with 10 ng KV2.1 over 48 h. 24 h post-transfection, HEK293 cells are either exposed to normal medium (control) containing 0.1% DMSO (vehicle control) or 0.1, 0.3, 1 or 3 μM retigabine for 4 h. After the 4 h exposure, the incubation medium is removed and fresh medium is added to the transfected HEK293 cells. Thus, at the moment of electrophysiological analysis (48 h post-transfection), no retigabine is present in the recording solution.
Animal Study:^{^[5]}	Animal Models DBA/2 mice Dosages 0.5-20 mg/kg Administration i.p.

Cell Assay:^{^[3]}

Cell lines
HEK293 cells
Concentrations
0.1, 0.3, 1 or 3 μM
Incubation Time
4 h
Method
The retigabine incubation experiments are performed on HEK293 cells transfected with 10 ng KV2.1 over 48 h. 24 h post-transfection, HEK293 cells are either exposed to normal medium (control) containing 0.1% DMSO (vehicle control) or 0.1, 0.3, 1 or 3 μM retigabine for 4 h. After the 4 h exposure, the incubation medium is removed and fresh medium is added to the transfected HEK293 cells. Thus, at the moment of electrophysiological analysis (48 h post-transfection), no retigabine is present in the recording solution.

Animal Study:^{^[5]}

Animal Models
DBA/2 mice
Dosages
0.5-20 mg/kg
Administration
i.p.

References

+ Expand

Selleck's Retigabine 2HCl has been cited by 4 publications

The SUMO-specific protease SENP2 plays an essential role in the regulation of Kv7.2 and Kv7.3 potassium channels [ J Biol Chem, 2021, S0021-9258(21)00985-6]	PubMed: 34509475
The Changes of KCNQ5 Expression and Potassium Microenvironment in the Retina of Myopic Guinea Pigs [ Front Physiol, 2021, 12:790580]	PubMed: 35002772
Depolarization-Dependent C-Raf Signaling Promotes Hyperexcitability and Reduces Opioid Sensitivity of Isolated Nociceptors after Spinal Cord Injury [ J Neurosci, 2020, 40(34):6522-6535]	PubMed: 32690613
KCNQ2/3/5 channels in dorsal root ganglion neurons can be therapeutic targets of neuropathic pain in diabetic rats [ Mol Pain, 2018, 14:1744806918793229]	PubMed: 30027794

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.